CNS Response, Inc. (CNSO.OB) Awarded Third U.S. Patent Targeting the Development of New Indications for Existing Drugs
CNS Response, Inc. announced that it has received a patent from the U.S. Patent and Trademark Office. The patent, numbered 7,489,964 and titled “Electroencephalography Based Systems and Methods for Selecting Therapies and Predicting Outcomes”, extends application of rEEG® technology to novel methods that can expand indications for CNS pharmaceuticals. "One of the most compelling opportunities in pharmaceutical marketing is the ability to expand new indications for already approved medications," commented CNS Response CEO Len Brandt. "With the successful completion of our multisite study for the treatment of resistant depression, I believe we will have demonstrated the utility of the rEEG…